1063 patents
Page 13 of 54
Utility
a Combination of a BTK Inhibitor and Abatacept for the Treatment of Rheumatoid Arthritis
5 Jan 23
Disclosed is method of treating a patient having rheumatoid arthritis, comprising administering sequentially to said patient, a therapeutically effective dose of branebrutinib for a first period, followed by a therapeutically effect dose of abatacept for a second period.
Dennis Michael Grasela
Filed: 24 Nov 20
Utility
Biomarkers for Nanoparticle Compositions
5 Jan 23
The present application provides methods and compositions for treating cancer by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and a carrier protein (such as an albumin) based upon the mutation status of TSC1 or TSC2 and one of VHL, RBI, PBRIM1, K.DM6A, RET, SETD2 ARID 1 A, BAP1, BRCA2, TP53, RBI, ATRX, FLT1, NTRK1, TLX3, KDM6A, CDH4, CDKN2C, DAXX, ERBB3, GNAS, IL7R, PDGFRB, PMS2, PTEN, SMARCA4, and YY1AP1.
Neil P. DESAI, Anita N. SCHMID, Shihe HOU, Andrew KWON
Filed: 11 Nov 20
Utility
Compositions for Cell Bioproduction and Methods of Using the Same
5 Jan 23
The present invention relates to new methods and processes for culturing mammalian cells with the addition of phenolic antioxidants.
JUN TIAN, Jianlin Xu, Qin He
Filed: 1 Jul 21
Reissue
Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
3 Jan 23
Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Badu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
Filed: 3 Sep 20
Utility
Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
3 Jan 23
In certain embodiments, the disclosure provides an IgG4 antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises: (a) a modified IgG4 CH1 region having a substitution of the lysine residue at position 196; or (b) a modified IgG4 hinge region having a substitution of the serine residue at position 217, the glycine residue at position 220, the proline residue at position 224 or the proline residue at position 225.
Zhiqiang Chen, Yueming Qian, Xuankuo Xu, Chao Huang, Zhijun Tan, Zhengjian Li
Filed: 22 Dec 17
Utility
Ligand-directed covalent modification of protein
3 Jan 23
The present invention relates to enzyme inhibitors.
Russell C. Petter, Charles F. Jewell, Kwangho Lee, Aravind Prasad Medikonda, Deqiang Niu, Lixin Qiao, Juswinder Singh, Zhendong Zhu
Filed: 2 Feb 17
Utility
Substituted Heterocyclic Compounds
29 Dec 22
Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Joseph A. Tino, Shoshana L. Posy, Sirish Kaushik Lakkaraju, Zili Xiao, James Kempson
Filed: 13 May 22
Utility
LAG-3 Antagonist Therapy for Melanoma
29 Dec 22
The disclosure provides a method of treating unresectable or metastatic melanoma in a human patient with a lymphocyte activation gene-3 (LAG-3) antagonist.
Shivani SRIVASTAVA, Mena ABASKHAROUN
Filed: 6 Nov 20
Utility
Histone demethylase inhibitors
27 Dec 22
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease.
Amogh Boloor, Toufike Kanouni, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
Filed: 21 Sep 20
Utility
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
27 Dec 22
This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker.
Jeffrey Greve
Filed: 30 Dec 19
Utility
Miniaturized dystrophins having spectrin fusion domains and uses thereof
27 Dec 22
Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin.
Glen Banks, Jonathan Harry Davis, Paul Charles Levesque
Filed: 28 Apr 21
Utility
Human Monoclonal Antibodies to FUCOSYL-GM1 and Methods for
Using ANTI-FUCOSYL-GM1 Antibodies
22 Dec 22
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity.
Cynthia A. VISTICA, Eric H. HOLMES, Peter BRAMS, Alison WITTE, Josephine M. CARDARELLI
Filed: 5 Aug 22
Utility
Substituted Benzimidazoles As PAD4 Inhibitors
22 Dec 22
Daniel S. Gardner, John V. Duncia, Joseph B. Santella, Khehyong Ngu, Christopher Annunziato
Filed: 7 Aug 19
Utility
Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
20 Dec 22
Nicholas R. Wurtz, Pravin Sudhakar Shirude
Filed: 11 Jun 20
Utility
GLP-1 receptor modulators
20 Dec 22
Junko Tamiya, Philip Turnbull, Brahmachary Enugurthi, Liming Huang, Adam R. Yeager, Thomas Fowler, Greg P. Iacobini, Matthew Richard Crittall
Filed: 26 Apr 18
Utility
Anti-ICOS agonist antibodies and uses thereof
20 Dec 22
The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity.
John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
Filed: 14 Oct 19
Utility
Radially Adjustable Multi-cartridge Combinatorial Drug Delivery Device for Subcutaneous Injection
15 Dec 22
In one aspect, a drug delivery device is provided for delivering drug from a plurality of drug cartridges.
Martin John McLoughlin, Stephen Lawrence Zieminski, Peter William Heyman, Mark Steven Howansky, Frank Berardocco, Samuel Robert Zschack, Melanie Marie Springer, Jonathan Adam Reed, Joseph Morin
Filed: 9 Nov 20
Utility
Methods to Manipulate Quality Attributes of Polypeptides Produced In Cho Cells
15 Dec 22
In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides.
Jun TIAN
Filed: 2 Jun 22
Utility
Indole and azaindole inhibitors of pad enzymes
13 Dec 22
Anurag S. Srivastava, Robert J. Cherney, Khehyong Ngu
Filed: 7 Aug 19
Utility
Glypican-3-binding fibronectin based scaffold molecules
13 Dec 22
Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3.
Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
Filed: 24 Jan 20